Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and PD-1 Inhibitors Versus Lenvatinib Plus PD-1 Inhibitors as First-line Treatment for High Tumor Burden Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: a Target Trial Emulation Study

NCT06631326 is registered in ClinicalTrials.gov with First Hospital of China Medical University as lead sponsor.

NCT NCT06631326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06631326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and PD-1 Inhibitors Versus Lenvatinib Plus PD-1 Inhibitors as First-line Treatment for High Tumor Burden Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: a Target Trial Emulation Study
Lead sponsor
First Hospital of China Medical University
Phase
Observational
Overall status
Completed
Start date
January 1, 2021
Completion date
October 22, 2025
Enrollment
244 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bclc stage c hepatocellular carcinoma, hcc - hepatocellular carcinoma, hepatic arterial infusion chemotherapy, lenvatinib, pd-1 inhibitors